RATIONALE: Intermittent hypoxia, a hallmark of sleep apnea, is a major factor for hypertension and impaired vasoreactivity. OBJECTIVES: To examine the temporal occurrence of these two outcomes in order to provide insight into mechanisms and early cardiovascular disease identification. METHODS: Functional and structural cardiovascular alterations were assessed in C57BL6 mice exposed to intermittent hypoxia (21-4% Fi(O(2)), 30-s cycle, 8 h/d) or air for up to 35 days. Blood pressure, heart rate, and urinary catecholamines were measured at Days 1 and 14. Hindquarter vasoreactivity was assessed at Days 14 and 35, including vasoconstriction to norepinephrine, endothelium-, and non-endothelium-dependent vasodilation. Aorta, heart, and hindquarter skeletal muscles were immunostained for vascular markers PECAM-1 and collagen IV. MEASUREMENTS AND MAIN RESULTS: Hemodynamic alterations occurred from Day 1, characterized by blood pressure surges with bradytachyarrhythmia driven by cyclic hypoxia. At Day 14, blood pressure at normoxia was elevated, with predominant diastolic increase. With hypoxia, vasopressive catecholamines were elevated, blood pressure surged with a lower hypoxic threshold, whereas heart rate fluctuations decreased. Histologic alterations started from Day 14, with decreased endothelial PECAM-1 expression in descending aorta and left heart. Impaired peripheral vasoreactivity occurred at Day 35, including hypervasoconstriction to norepinephrine secondary to sympathetic hyperactivity, without changes in pre- and postsynaptic alpha-adrenoceptors or in endothelium- and non-endothelium-dependent vasodilation. CONCLUSIONS: Intermittent hypoxia induces sequential cardiovascular events suggesting increased chemoreflex and depressed baroreflex, resulting in sympathoadrenal hyperactivity, early hemodynamic alterations with proximal histologic remodeling, and delayed changes in peripheral vasoreactivity. Such early alterations before overt cardiovascular disease strengthen the need for identifying at-risk individuals for systematic treatment.
RATIONALE: Intermittent hypoxia, a hallmark of sleep apnea, is a major factor for hypertension and impaired vasoreactivity. OBJECTIVES: To examine the temporal occurrence of these two outcomes in order to provide insight into mechanisms and early cardiovascular disease identification. METHODS: Functional and structural cardiovascular alterations were assessed in C57BL6 mice exposed to intermittent hypoxia (21-4% Fi(O(2)), 30-s cycle, 8 h/d) or air for up to 35 days. Blood pressure, heart rate, and urinary catecholamines were measured at Days 1 and 14. Hindquarter vasoreactivity was assessed at Days 14 and 35, including vasoconstriction to norepinephrine, endothelium-, and non-endothelium-dependent vasodilation. Aorta, heart, and hindquarter skeletal muscles were immunostained for vascular markers PECAM-1 and collagen IV. MEASUREMENTS AND MAIN RESULTS: Hemodynamic alterations occurred from Day 1, characterized by blood pressure surges with bradytachyarrhythmia driven by cyclic hypoxia. At Day 14, blood pressure at normoxia was elevated, with predominant diastolic increase. With hypoxia, vasopressive catecholamines were elevated, blood pressure surged with a lower hypoxic threshold, whereas heart rate fluctuations decreased. Histologic alterations started from Day 14, with decreased endothelial PECAM-1 expression in descending aorta and left heart. Impaired peripheral vasoreactivity occurred at Day 35, including hypervasoconstriction to norepinephrine secondary to sympathetic hyperactivity, without changes in pre- and postsynaptic alpha-adrenoceptors or in endothelium- and non-endothelium-dependent vasodilation. CONCLUSIONS: Intermittent hypoxia induces sequential cardiovascular events suggesting increased chemoreflex and depressed baroreflex, resulting in sympathoadrenal hyperactivity, early hemodynamic alterations with proximal histologic remodeling, and delayed changes in peripheral vasoreactivity. Such early alterations before overt cardiovascular disease strengthen the need for identifying at-risk individuals for systematic treatment.
Authors: Ronghua Yang; Gautam Sikka; Jill Larson; Vabren L Watts; Xiaolin Niu; Carla L Ellis; Karen L Miller; Andre Camara; Christian Reinke; Vladimir Savransky; Vsevolod Y Polotsky; Christopher P O'Donnell; Dan E Berkowitz; Lili A Barouch Journal: Am J Physiol Heart Circ Physiol Date: 2011-01-28 Impact factor: 4.733
Authors: Qiaoling Yao; Mi-Kyung Shin; Jonathan C Jun; Karen L Hernandez; Neil R Aggarwal; Jason R Mock; Jason Gay; Luciano F Drager; Vsevolod Y Polotsky Journal: J Lipid Res Date: 2013-02-05 Impact factor: 5.922
Authors: Bradley R Webster; Jessica M Osmond; Daniel A Paredes; Xavier A DeLeon; Olan Jackson-Weaver; Benjimen R Walker; Nancy L Kanagy Journal: J Pharmacol Exp Ther Date: 2012-10-23 Impact factor: 4.030
Authors: Rachel E Nisbet; Anitra S Graves; Dean J Kleinhenz; Heidi L Rupnow; Alana L Reed; Tai-Hwang M Fan; Patrick O Mitchell; Roy L Sutliff; C Michael Hart Journal: Am J Respir Cell Mol Biol Date: 2008-10-23 Impact factor: 6.914
Authors: Valdir A Braga; Melissa A Burmeister; Ram V Sharma; Robin L Davisson Journal: Am J Physiol Regul Integr Comp Physiol Date: 2008-07-30 Impact factor: 3.619
Authors: Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White Journal: Hypertension Date: 2018-11 Impact factor: 10.190